Journal article
Improving economic evaluations in stroke: A report from the ESO Health Economics Working Group
DA Cadilhac, J Kim, A Wilson, E Berge, A Patel, M Ali, J Saver, H Christensen, M Cuche, S Crews, O Wu, M Provoyeur, P McMeekin, I Durand-Zaleski, GA Ford, N Muhlemann, PM Bath, AH Abdul-Rahim, K Sunnerhagen, A Meretoja Show all
European Stroke Journal | Published : 2020
Abstract
Introduction: Approaches to economic evaluations of stroke therapies are varied and inconsistently described. An objective of the European Stroke Organisation (ESO) Health Economics Working Group is to standardise and improve the economic evaluations of interventions for stroke. Methods: The ESO Health Economics Working Group and additional experts were contacted to develop a protocol and a guidance document for data collection for economic evaluations of stroke therapies. A modified Delphi approach, including a survey and consensus processes, was used to agree on content. We also asked the participants about resources that could be shared to improve economic evaluations of interventions for..
View full abstractGrants
Awarded by National Health and Medical Research Institute (SRF)
Funding Acknowledgements
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: DAC has received funding from the National Health and Medical Research Institute (SRF #1154273), and educational grants unrelated to this work from Boehringer Ingelheim, Shire, Medtronic, Allergan, Pfizer paid to her institution. AP has received funding for stroke research from the National Institute for Health Research (UK) and the Stroke Association (UK). MA the NMAHP Research Unit is funded by the Chief Scientist Office, (CSO) Scottish Government's Health and Social Care Directorate, Scotland. The views expressed here are those of the authors and not necessarily those of the CSO. JLS is an employee of the University of California, which has patent rights in retrieval devices for stroke; has received contracted hourly payments for services as a scientific consultant advising on rigorous trial design and conduct to Medtronic, Stryker, Johnson and Johnson, BrainsGate, Boehringer Ingelheim (prevention only), Diffusion Medical and Abbott; has received contracted stock options for services as a scientific consultant advising on rigorous trial design and conduct to Rapid Medical. HC has received speaker honoraria, travel expenses and/or consulting fees from Boehringer-Ingelheim, MSD, Bayer, and Medtronic. MC works for Medtronic International, neurovascular division. OW has received honorarium and/or consultancy fees from Bayer and Lupin, as well as research funding from Novo Nordisk. PM has received payments for consultancy and/or educational work from Medtronic. IDZ has received speaker honoraria, travel expenses and/or consulting fees from BoehringerIngelheim, Sanofi, MSD, BMS, Abbvie, Medtronic. GAF has received payments for consultancy and/or educational work from Amgen, Daiichi Sankyo, Medtronic, Pfizer and Stryker. He is a National Institute of Health Research Senior Investigator. NM is an employee of Nestle Health Science, Nestec S. A. PMB has received consulting fees, speaker honoraria and/or travel expenses from DiaMedica, Nestle, Moleac, Phagenesis, ReNeuron, Sanofi. He is Stroke Association Professor of Stroke Medicine and is a National Institute of Health Research Senior Investigator. KSS has performed studies for the Swedish national board of health and welfare. Has received speaker honoraria from Allergan. AMe has received speaker honoraria, travel expenses, and/or consulting fees from Boehringer-Ingelheim, Stryker, MSD, Nestec and Phagenesis. VT has received speaker honoraria, travel expenses and consulting fees from Bayer, Boehringer Ingelheim, Amgen, Shire and Pfizer. CW has received honoraria for advisory boards or lectures from Alexion, Amgen, Bayer-Schering as well as research funding from Boehringer Ingelheim. KRL has received fees and expenses from ACI Clinical, American Heart Association, Boehringer Ingelheim, EVER NeuroPharma, Hilicon and Parexel.